HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Tadalafil
CIALIS · Tadanafil · Tadalafei · Taladafil · tadanafei · Calais · Tadalfil · Tildenafil

Identifikatoren & physikalische Daten
| CAS No. | 171596-29-5 |
|---|---|
| Summenformel | C22H19N3O4 |
| Durchschnittliche Molmasse | 389,4 g/mol |
| Monoisotopische Masse | 389,13755609 g/mol |
| SMILES | CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O |
| InChIKey | WOXKDUGGOYFFRN-IIBYNOLFSA-N |
| PubChem CID | 110635 |
| ChEMBL | CHEMBL779 |
| ChEBI | CHEBI:71940 |
| EC No. | 687-782-2 |
| DTXSID | DTXSID9046786 |
Chemische & physikalische Eigenschaften
| XLogP | 2,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 74,9 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 4 |
| Frei drehbare Bindungen | 1 |
| Schwere Atome | 29 |
| Formalladung | 0 |
| Komplexität | 702 |
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15 |
| LogP (Verteilungskoeffizient) | log Kow = 1.42 /Estimated/1.72.6 |
| Löslichkeit | Practically insoluble in waterIn water, 220 mg/L at 25 °C /Estimated/2.50e-01 g/L3.2 [ug/mL] (The mean of the results at pH 7.4)DMSO: soluble20mg/mL, clear |
| Human Drugs | FDA approved drugs -> Active ingredientEMA approved medicines: Human medicine |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Schmelzpunkt | 301-302 °C301 - 302 °C298-300°C |
| Dampfdruck | 2.2X10-14 mm Hg at 25 °C /Estimated/ |
| Henry-Konstante | Henry's Law constant = 5.0X10-18 atm-cu m/mol @ 25 °C /Estimated/2.0×1012 mol/(m3Pa) at 25℃, HSDB (2015) |
| Physical Description | Solid |
| Dissociation Constants | pKa = 0.85 /Estimated/ |
| Collision Cross Section | 199.71 Ų [M+K]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]189.4 Ų [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]188.7 Ų [M+H]+ [CCS Type: TW |
| Other Experimental Properties | Hydroxyl radical reaction rate constant = 2.9X10-10 cu cm/molec-sec at 25 °C /Estimated/ |
| Siedepunkt | 679.1±55.0 °C(Predicted) |
| Dichte | 1.51±0.1 g/cm3(Predicted) |
| Flammpunkt | 2℃ |
| Lagerbedingungen | Sealed in dry,2-8°C |
| Aggregatzustand | powder |
| pKa (Säurekonstante) | 16.68±0.40(Predicted) |
| Farbe | white to beige |
| BCS Class | 4 |
| Stabilität | Unstable in Methanol |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChI | InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1 |
| InChIKey | WOXKDUGGOYFFRN-IIBYNOLFSA-N |
| SMILES | N1C2=C(C=CC=C2)C2C[C@]3([H])C(=O)N(C)CC(=O)N3[C@H](C3=CC=C4OCOC4=C3)C1=2 |
| CAS Datenbank | 171596-29-5(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH302 (54.8%): Harmful if swallowed [Warning Acute toxicity, oral]P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 104 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| FDA-Anforderungen | The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl tadalafil, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. |
| Hazard Classes and Categories | Acute Tox. 4 (54.8%) |
| Entsorgungsverfahren | SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air qualitypotential migration in soil or watereffects on animal, aquatic, and plant lifeand conformance with environmental and public health regulations. |
| Wechselwirkungen | Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and tadalafil reduced the apparent rate of absorption of tadalafil without altering the exposure (AUC) to tadalafil.A significant interaction between tadalafil and nitroglycerin was observed to last up to 48 hoursat least 48 hours should elapse after the last dose of tadalafil before nitrate administration is considered.Administration of tadalafil to patients who are using any form of organic nitrates, either regularly and/or intermittently, is contraindicatedin clinical pharmacology studies tadalafil was shown to potentiate the hypotensive effects of nitratesthis is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway.The safety and efficacy of combinations of tadalafil and other erectile dysfunctions have not been studied |
Anwendungen & Verwendung
Beschreibung
Tadalafil (market name “Cialis” or “Adcirca”) was developed by American pharmaceutical company Lilly. It is a kind of PDE5 inhibitor used for the treatment of erectile dysfunction, benign prostatic hypertrophy and pulmonary arterial hypertension.The effect of Tadalafil is relaxing the blood vessels muscles and increasing the blood flow into the corpus cavernosum. Studies show that Cialis works very quickly, taking effect in around 15-20 minutes, and has a prolonged effect that can last for up to 36 hours. T1/2 is 17.5h.